Nephro Care India Ltd IPO Timeline

Nephro Care India Ltd IPO opens on 28-Jun-2024, and closes on 02-Jul-2024. The Nephro Care India Ltd IPO bid date is from 28-Jun-2024 to 02-Jul-2024. The Cut-off time for UPI Mandate confirmation is 12 P.M. on the next day of issue closing day.

Event Date
Nephro Care India Ltd IPO Opening Date 28-Jun-2024
Nephro Care India Ltd IPO Closing Date 02-Jul-2024
Basis of Allotment 03-Jul-2024
Initiation of Refunds 04-Jul-2024
Credit of Shares to Demat 04-Jul-2024
Nephro Care India Ltd IPO Listing Date 05-Jul-2024

Nephro Care India Ltd IPO Lot Size

Nephro Care India Ltd IPO lot size is 1600 shares. A retail-individual investor can apply for up to 1 lots (1600 shares or 144000).

Application Lots Shares Amount
Minimum 1 1600 ₹144000
Maximum 1 1600 ₹144000

Nephro Care India Ltd IPO Details

Nephro Care India Ltd IPO Date 28-Jun-2024 to 02-Jul-2024
Nephro Care India Ltd IPO Face Value Shares of ₹10 per share
Nephro Care India Ltd IPO Price ₹85 to ₹90 per share
Nephro Care India Ltd IPO Lot Size 1600
Issue Size Shares of ₹10 (aggregating up to ₹41.26 Cr)
Fresh Issue Shares of ₹10 (aggregating up to ₹41.26 Cr)
Offer for Sale -
Issue Type Book Building - SME
Listing At NSE - SME
QIB Shares Offered -
Retail Shares Offered -
NII (HNI) Shares Offered -
Company Promoters Pratim Sengupta.

Objects of the Issue

The company proposes to utilise the Net Proceeds from the Fresh Issue towards funding the following objects:

  • 1 Setting up a Multi Speciality Hospital in the name of "Vivacity Multi Specialty Hospital" (unit of Nephro Care) (Madhyamgaram)
  • 2 General Corporate Expenses

Company Financials

Nephro Care India Ltd Financial Information (Restated)

Period Ended Total Assets Total Revenue Profit After Tax
03-2024 20.97 27.60 4.41
03-2023 8.26 17.09 2.37
03-2022 4.63 3.43 -0.01
Amount in ₹ Crore
  • We bridge the gap between day care and tertiary care services by addressing unmet needs through a blend of modern medical science and time tested yogic wisdom for overall wellbeing of the patients.
  • Our technology backbone is robust and supports consistent improvements in the quality and efficiency of our service delivery.
  • Track record of operating and financial performance and growth.
  • Professional management and experienced leadership.
  • Investment in infrastructure, processes and clinical services delivery framework, affordability resulting in a strong value proposition for stakeholders.
  • Its Promoter, Dr. Pratim Sengupta, plays a key role in the company functioning and its heavily relies on his knowledge and experience in operating its business and therefore, it is critical for the company's business that its Promoter remain associated with the company.
  • Its expansion into new business vertical, i.e. setting up a hospital, may expose the company to new challenges and more risks.
  • The company's revenues are significantly dependent on its flagship Salt Lake clinic. Further, all its clinics are located in the Kolkata. Any impact on the revenues of its flagship Salt Lake clinic or any change in the economic or political circumstances of West Bengal or particularly in or around Kolkata, could materially affect its business, financial condition and results of operations.
  • The company is highly dependent on its healthcare professionals including doctors and nurses, and any future inability to attract/ retain such professionals will adversely affect its business, financial condition and results of operations.
  • Its industry is highly regulated and requires it to obtain, renew and maintain statutory and regulatory permits, accreditations, licenses and comply with applicable safety, health, environmental, labour and other governmental regulations. Any regulatory changes or violations of such rules and regulations may adversely affect its business, financial condition and results of operations.
  • The company incur high expenses in relation to manpower cost, infrastructure and medical maintenance and repair costs, ancillary and various pharmaceuticals items. If the company is unable to obtain favourable pricing from suppliers or negotiate compensation of its healthcare professionals effectively, it could affect its profitability. Any inability to pass on such costs to its patients, may have an adverse impact on its business, financial condition and results of operations.
  • There can be no assurance that the objects of the Issue will be achieved within the time frame anticipated or at all, or that the deployment of the Net Proceeds in the manner intended by it will result in any increase in the value of your investment. Further, the plan for deployment of the Net Proceeds has not been appraised by any bank or financial institution.
  • Its ability to provide affordable healthcare depends on the maintenance of a high volume of patients and effective capital management. Any increase in such costs could adversely affect its business, financial condition and results of operations.
  • The Company is yet to place orders for the equipments and machines required for its proposed multi-speciality hospital. Any delay in placing orders or procurement of such equipment, may further delay the schedule of implementation and increase the cost of commissioning the manufacturing units.
  • The company may experience delays in commencement of operations of its proposed hospital or the company may be unsuccessful in implementing its growth plans of expansion in a timely manner or at all, which may have an adverse effect on its business, financial condition and results of operations.
  • The company is dependent upon the experience and skill of its management team, a number of key managerial personnel and senior management personnel. If the company is unable to attract or retain such qualified personnel, this could adversely affect its business, financial condition and results of operations.
  • Pricing regulations and related government reforms in the healthcare industry and associated uncertainty may adversely affect its business, financial condition and results of operations.
  • The company could be exposed to risks relating to the handling of personal information, including medical data.
  • An inability to keep pace with technological changes, new equipment, replacement of obsolete equipment and service introductions, changes in patients' needs and evolving industry standards as well as failure or malfunction of its medical or other equipment could adversely affect the company's business, financial condition and results of operations.
  • Any failures to maintain and enhance its brand and reputation, and any negative publicity and allegations in the media against it, may adversely affect the level of trust in its services and market recognition, which could further result in an adverse impact on its business, financial condition and results of operations.
  • The company faces competition from other healthcare service providers and an inability to compete effectively could adversely affect its business, financial condition and results of operations.
  • An inability to maintain optimum levels of doctor-patient ratio at its clinics and the company proposed hospitals could adversely affect its business, operations, financial condition and results of operations.
  • Any failures to provide quality medical treatment and service to its patients and any lapses on part of the company's medical staff may adversely affect the reputation of its hospitals, and as a result, its business, financial condition and results of operations.
  • Its insurance coverage may not be sufficient to cover all possible economic losses, which could have an adverse effect on its business, financial condition and results of operations.
  • An inability to protect its intellectual property rights, or any exposure to misappropriation and infringement claims by third parties, could have an adverse effect on its business, reputation, financial condition and results of operations.
  • In the past, there have been discrepancy and the instances of delays in filing of certain forms which were required to be filed as per the reporting requirements under the Companies Act, 2013 to RoC.
  • Its patients may contract serious communicable infections or diseases at its clinics due to the risks typically associated with the operation of medical care facilities.
  • An inability to establish and maintain effective internal controls could lead to an adverse effect on its business and reputation.
  • Its Promoters, Directors and Key Managerial Personnel have interests in the Company other than reimbursement of expenses incurred or normal remuneration or benefits.
  • Its Promoters and members of the Promoter Group have significant control over the Company and have the ability to direct its business and affairs; their interests may conflict with your interests as a shareholder.
  • The average cost of acquisition of Equity Shares held by its Promoters could be lower than the Issue Price.
  • The company has in past entered into related party transactions and its may continue to do so in the future.
  • The company use highly flammable materials in its activities which expose the company to the risk of loss due to fire. Any fire accidents may have a material adverse effect on its business, financial condition and results of operations.
  • Any conflict of interest which may occur between its business and any other similar business activities pursued by its Promoters could have a material adverse effect on the company's business and results of operations.
  • The company has not made any alternate arrangements for meeting its capital requirements for the Objects of the Issue. Further, the company has not identified any alternate source of financing the 'objects of the Issue'. Any shortfall in raising / meeting the same could adversely affect its growth plans, operations and financial performance.
  • The company may faces difficulties in implementing its strategies including the company's expansion and diversification plans of entering new geographical areas, development and commercialization of new products.
  • The deployment of funds raised through this Issue shall not be subject to any Monitoring Agency and shall be purely dependent on the discretion of the management of the Company.
  • Any variation in the utilisation of the Net Proceeds or in the terms of any contract as disclosed in the Draft Red Herring Prospectus would be subject to certain compliance requirements, including prior shareholders' approval.
  • The requirement of funds in relation to the objects of the Issue has not been appraised.
  • Its ability to pay dividends in the future may be affected by any material adverse effect on its future earnings, financial condition or cash flows.
  • The company has not independently verified certain data in this Draft Red Herring Prospectus.
  • The requirements of being a listed company may strain its resources.
  • The Equity Shares have never been publicly traded and the Issue may not result in an active or liquid market for the Equity Shares.
  • There is no guarantee that the Equity Shares issued pursuant to the Issue will be listed on the SME Platform of National Stock Exchange of India Limited in a timely manner or at all.
  • There is no existing market for its Equity Shares, and the company does not know if one will develop to provide you with adequate liquidity. Further, an active trading market for the Equity Shares may not develop and the price of the Equity Shares may be volatile.
  • The price of the Equity Shares may be highly volatile after the Issue.
  • The price of the Equity Shares may be volatile, which could result in substantial losses for investors acquiring the Equity Shares in the Issue.
  • Any future issuance of Equity Shares, or convertible securities or other equity-linked securities by the Company may dilute your shareholding and any sale of Equity Shares by its Promoter or members of its Promoter Group may adversely affect the trading price of the Equity Shares.
  • Sale of Equity Shares by its Promoter or other significant shareholder(s) may adversely affect the trading price of the Equity Shares.
  • Continue to invest in extension of our Hub-and-Spoke network.
  • Continue to attract, engage and train prominent, skilled doctors and other healthcare professionals.
  • Enhance clinical capabilities and improve operating efficiencies.
  • Extend clinical services outside the clinic and across the lifetime of the patient.
  • Leverage technology to improve patient experience and grow our digital health services.
  • Build on our thought leadership through increased focus on academics and research.

Nephro Care India Ltd IPO Promoter Holding

Pre Issue Share Holding 84.02%
Post Issue Share Holding 0%

Nephro Care India Ltd IPO Subscription Status (Bidding Detail)

The Nephro Care India Ltd IPO is subscribed - times on Jul 02, 2024 05:00:00 PM. The public issue subscribed - times in the retail category, - times in the QIB category, and - times in the NII category. Check Day by Day Subscription Details (Live Status)

Category QIB NII Retail Employee Total
Subscription (times) - - - - -

Nephro Care India Ltd IPO Prospectus

Nephro Care India Ltd IPO Listing Date

Listing Date 05 Jul 24
BSE Script 92991
NSE Symbol NEPHROCARE
Listing In NSE - SME
ISIN INE0SUN01013
IPO Price -
Face Value ₹10

Nephro Care India Ltd IPO Registrar

Bigshare Services Pvt Ltd

Phone: +91-22-62638200
Email: ipo@bigshareonline.com
Website: www.bigshareonline.com

Nephro Care India Ltd IPO Lead Manager(s)

  1. Corporate Capitalventures Pvt Ltd

FAQs on Nephro Care India Ltd IPO

Nephro Care India Ltd IPO, which opens for subscription from 28-Jun-2024 to 02-Jul-2024 has an issue size of ₹41.26 crore. The issue type is book building issue.

In case of pre-apply, your IPO order will be placed on the Exchange as soon as the official bidding for Nephro Care India Ltd IPO begins. You will receive a UPI request within 24 hours after the bidding period opens.

Nephro Care India Ltd IPO Opens for subscription from 28-Jun-2024 to 02-Jul-2024.

The lot size of Nephro Care India Ltd is 1600 shares. Retail investors can subscribe to minimum 1 lot and maximum 1 lots. The minimum and maximum application value is ₹144000 and ₹144000 respectively.

Allotment date for Nephro Care India Ltd is 03-Jul-2024 and refund of application amount (in case allotment is not received) will begin from 04-Jul-2024. If your allotment goes through, then shares will be credited in your Demat account by 04-Jul-2024.

The registrar for Nephro Care India Ltd IPO is Bigshare Services Pvt Ltd . You can check your IPO allotment status on the registrar's website.

The shares of Nephro Care India Ltd are proposed to be listed on Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).

Power your investments with our smart trading platforms

mobilefooterimg
  • app_download_icon_img
    10 million+
    App downloads
  • 1_Click_icon_img
    1-Click
    Order Placement
  • higherreturns_icon_img
    2,203 Crore+
    Average Daily Turnover
Download App
App_Download_QRCode